301 related articles for article (PubMed ID: 17470792)
1. Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers.
Geering B; Cutillas PR; Nock G; Gharbi SI; Vanhaesebroeck B
Proc Natl Acad Sci U S A; 2007 May; 104(19):7809-14. PubMed ID: 17470792
[TBL] [Abstract][Full Text] [Related]
2. Regulation of class IA PI3Ks: is there a role for monomeric PI3K subunits?
Geering B; Cutillas PR; Vanhaesebroeck B
Biochem Soc Trans; 2007 Apr; 35(Pt 2):199-203. PubMed ID: 17371237
[TBL] [Abstract][Full Text] [Related]
3. Quantitation of class IA PI3Ks in mice reveals p110-free-p85s and isoform-selective subunit associations and recruitment to receptors.
Tsolakos N; Durrant TN; Chessa T; Suire SM; Oxley D; Kulkarni S; Downward J; Perisic O; Williams RL; Stephens L; Hawkins PT
Proc Natl Acad Sci U S A; 2018 Nov; 115(48):12176-12181. PubMed ID: 30442661
[TBL] [Abstract][Full Text] [Related]
4. Role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement.
Brachmann SM; Yballe CM; Innocenti M; Deane JA; Fruman DA; Thomas SM; Cantley LC
Mol Cell Biol; 2005 Apr; 25(7):2593-606. PubMed ID: 15767666
[TBL] [Abstract][Full Text] [Related]
5. Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice.
Brachmann SM; Ueki K; Engelman JA; Kahn RC; Cantley LC
Mol Cell Biol; 2005 Mar; 25(5):1596-607. PubMed ID: 15713620
[TBL] [Abstract][Full Text] [Related]
6. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.
Dornan GL; Burke JE
Front Immunol; 2018; 9():575. PubMed ID: 29616047
[TBL] [Abstract][Full Text] [Related]
7. Dynamic steps in receptor tyrosine kinase mediated activation of class IA phosphoinositide 3-kinases (PI3K) captured by H/D exchange (HDX-MS).
Burke JE; Williams RL
Adv Biol Regul; 2013 Jan; 53(1):97-110. PubMed ID: 23194976
[TBL] [Abstract][Full Text] [Related]
8. Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase.
Chagpar RB; Links PH; Pastor MC; Furber LA; Hawrysh AD; Chamberlain MD; Anderson DH
Proc Natl Acad Sci U S A; 2010 Mar; 107(12):5471-6. PubMed ID: 20212113
[TBL] [Abstract][Full Text] [Related]
9. Cloning, expression, purification, and characterization of the human Class Ia phosphoinositide 3-kinase isoforms.
Meier TI; Cook JA; Thomas JE; Radding JA; Horn C; Lingaraj T; Smith MC
Protein Expr Purif; 2004 Jun; 35(2):218-24. PubMed ID: 15135396
[TBL] [Abstract][Full Text] [Related]
10. Class IA PI3K regulatory subunits: p110-independent roles and structures.
Fox M; Mott HR; Owen D
Biochem Soc Trans; 2020 Aug; 48(4):1397-1417. PubMed ID: 32677674
[TBL] [Abstract][Full Text] [Related]
11. The p85 regulatory subunit controls sequential activation of phosphoinositide 3-kinase by Tyr kinases and Ras.
Jimenez C; Hernandez C; Pimentel B; Carrera AC
J Biol Chem; 2002 Nov; 277(44):41556-62. PubMed ID: 12196526
[TBL] [Abstract][Full Text] [Related]
12. Class I phosphoinositide 3-kinase p110beta is required for apoptotic cell and Fcgamma receptor-mediated phagocytosis by macrophages.
Leverrier Y; Okkenhaug K; Sawyer C; Bilancio A; Vanhaesebroeck B; Ridley AJ
J Biol Chem; 2003 Oct; 278(40):38437-42. PubMed ID: 12869549
[TBL] [Abstract][Full Text] [Related]
13. Positive and negative regulation of phosphoinositide 3-kinase-dependent signaling pathways by three different gene products of the p85alpha regulatory subunit.
Ueki K; Algenstaedt P; Mauvais-Jarvis F; Kahn CR
Mol Cell Biol; 2000 Nov; 20(21):8035-46. PubMed ID: 11027274
[TBL] [Abstract][Full Text] [Related]
14. Nuclear but not cytosolic phosphoinositide 3-kinase beta has an essential function in cell survival.
Kumar A; Redondo-Muñoz J; Perez-García V; Cortes I; Chagoyen M; Carrera AC
Mol Cell Biol; 2011 May; 31(10):2122-33. PubMed ID: 21383062
[TBL] [Abstract][Full Text] [Related]
15. The regulation of class IA PI 3-kinases by inter-subunit interactions.
Backer JM
Curr Top Microbiol Immunol; 2010; 346():87-114. PubMed ID: 20544340
[TBL] [Abstract][Full Text] [Related]
16. A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase.
Dbouk HA; Pang H; Fiser A; Backer JM
Proc Natl Acad Sci U S A; 2010 Nov; 107(46):19897-902. PubMed ID: 21030680
[TBL] [Abstract][Full Text] [Related]
17. Increased insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase.
Ueki K; Yballe CM; Brachmann SM; Vicent D; Watt JM; Kahn CR; Cantley LC
Proc Natl Acad Sci U S A; 2002 Jan; 99(1):419-24. PubMed ID: 11752399
[TBL] [Abstract][Full Text] [Related]
18. Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.
Jiang X; Chen S; Asara JM; Balk SP
J Biol Chem; 2010 May; 285(20):14980-14989. PubMed ID: 20231295
[TBL] [Abstract][Full Text] [Related]
19. Positive and negative roles of p85 alpha and p85 beta regulatory subunits of phosphoinositide 3-kinase in insulin signaling.
Ueki K; Fruman DA; Yballe CM; Fasshauer M; Klein J; Asano T; Cantley LC; Kahn CR
J Biol Chem; 2003 Nov; 278(48):48453-66. PubMed ID: 14504291
[TBL] [Abstract][Full Text] [Related]
20. Differential regulation of class IA phosphoinositide 3-kinase catalytic subunits p110 alpha and beta by protease-activated receptor 2 and beta-arrestins.
Wang P; Kumar P; Wang C; Defea KA
Biochem J; 2007 Dec; 408(2):221-30. PubMed ID: 17680774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
